Printer Friendly

Boston Biomedical Research Institute and Wyeth announce licensing of Alzheimer's immunotherapy technology.

Boston Biomedical Research Institute (BBRI) (Watertown, MA) has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth to license BBRI's patented technology for immunotherapy to combat Alzheimer's disease. This agreement will further the Elan and Wyeth collaboration with BBRI on beta amyloid immunotherapy for the treatment of Alzheimer's disease. The ground- breaking work forming the basis for the patent applications was conducted in the lab of Dr. Vic Raso, a senior scientist at BBRI.

About the announcement, Dr. Charles Emerson, Director of BBRI said, "Dr. Raso's achievement is a validation of the power of investigator-initiated basic research in the development of innovative cures for devastating diseases. BBRI is dedicated to providing support for investigators like Dr. Raso who are doing innovative work that is not yet supported by conventional funding sources. There is a great need for more public and private support for research such as this at the very frontier of science, where there are no rewards without risk."

Alzheimer's disease is the most common cause of dementia, and the fourth leading cause of death in developed countries. It is estimated that more than four million people in the United States and between 6 and 7 million in Western Europe currently suffer from Alzheimer's disease, and its prevalence doubles every five years beyond age 65, up to an incidence of 1:3 in people in their 80's.

Under the terms of the licensing agreement, Wyeth will pay an up front licensing fee and will pay patent costs for the technology. Additional milestone payments are possible based on the issuance of certain BBRI patent claims, approval of a commercial product covered by issued patent claims, and royalties on that product. Specific terms of the agreement were not disclosed.

BBRI is an independent, not-for-profit institution, dedicated to basic biomedical research to promote the understanding, treatment, and prevention of human diseases, including heart disease, cancer, muscular dystrophy and Alzheimer's. Areas of research focus on biochemical molecular and cellular mechanisms of muscle contractility and cell movement, cell growth and differentiation, and tissue repair and regeneration.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non- prescription medicines that improve the quality of life for people worldwide.

Boston Biomedical Research Institute


Wyeth Pharmaceuticals

COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Nov 1, 2004
Previous Article:Gedeon Richter and Forest collaborate on atypical antipsychotic for schizophrenia, bipolar mania and other psychiatric disorders.
Next Article:Palatin Technologies expands patent portfolio in the treatment of sexual dysfunction.

Related Articles
Australian collaboration to develop world's first Alzheimer's vaccine.
Catalyst Biosciences licenses seminal intellectual property in the field of protease therapeutics.
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.
Wyeth forms translational collaboration with universities in Scotland.
Eisai and BioArctic Neuroscience Enter Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters